Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Genetics of Fabry Disease Clinical Presentation

  • Author: Robert J Desnick, MD, PhD; Chief Editor: Maria Descartes, MD  more...
 
Updated: Feb 24, 2016
 

History

Fabry disease should be considered in patients with the isolated features detailed below or in those who show signs of multisystemic involvement in a pattern consistent with renal, cardiac, and cerebrovascular involvement. A detailed and complete medical and family history and thorough physical examination are necessary.

A detailed medical and family history should be obtained, with emphasis on the following:

  • Presence, location, and density of skin rash (angiokeratoma)
  • Characteristics, frequency, and intensity of pain (acroparesthesia)
  • Bowel habits, abdominal cramping, vomiting, nausea, and food intolerance
  • History of abnormal sweating
  • Heat, cold, and exercise intolerance and easy fatigability
  • Family history of kidney failure, heart disease, stroke, or other signs or symptoms of Fabry disease in X-linked pattern of segregation
Next

Classic Fabry Disease

Patients with classic Fabry disease typically have α-Gal A activity of less than 1% and often demonstrate the full spectrum of symptoms. The 2 categories of classic disease manifestation are as follows:

Early manifestations

Early manifestations generally begin in childhood or adolescence and include the characteristic corneal and lenticular opacities, skin lesions (angiokeratoma), pain in the extremities (acroparesthesia), and decreased ability to sweat (hypohidrosis). In addition, patients may have chronic abdominal pain and diarrhea. Some patients may experience spontaneous relief of these early symptoms during adulthood (eg, symptomatic improvement of acroparesthesias).

The earliest reported symptom of Fabry disease is often intermittent or chronic acroparesthesias. These pain episodes are described as burning, tingling, and numbness and are thought to be related to the involvement of the vascular supply and small fibers of the peripheral nervous system. Pain, especially in the hands and feet, may occur daily and may vary in severity. These episodes may occur in both sexes and may begin as early as age 2 years. Pain may be triggered by a body temperature increase due to exercise, fever, emotional stress, or environmental temperature changes. Extreme pain attacks, referred to as Fabry pain crises, usually affect male patients and are described as severe episodes that last several hours to days. These episodes may be accompanied by low-grade fever, body pains, and fatigue.

GI manifestations of Fabry disease are common and are believed to be caused by the deposition of GL-3 in the small vessels and the autonomic ganglia of the intestine. GI symptoms often begin in adolescence and may worsen with age. Common manifestations include episodes of postprandial abdominal pain and bloating, followed by multiple bowel movements, diarrhea, nausea, vomiting, and early satiety. Symptoms are generally more frequent and appear earlier in life in males compared with female carriers.

Dermal manifestations of Fabry disease include cutaneous vascular lesions (angiokeratomas) and abnormal sweating (anhidrosis or, more commonly, hypohidrosis). Weakening of the capillary wall and vascular ectasia within the epidermis and dermis causes angiokeratomas. They usually manifest at age 5-13 years and initially appear as small, slightly raised, purplish-red, nonblanching angiectases. The number and size of these lesions progressively increase with age. Anhidrosis or hypohidrosis is also frequently reported and is thought to be secondary to lipid accumulation in the eccrine cells of the sweat glands and dysfunction of the autonomic nervous system.

Corneal manifestations are reported in more than 70-90% of patients. The best-known ocular symptom is a pattern of whitish spiral streaks in the corneal epithelium known as cornea verticillata.

Some patients may have recurrent fevers with no obvious source. Pain usually accompanies the fevers, and an elevated erythrocyte sedimentation rate may be present.

Disease symptoms and implications may affect the patient's school performance, level of activity, and mental health.

Late and serious clinical manifestations of Fabry disease

During the late stage of the disease, the progressive deterioration of renal, cardiac, and nervous system function ultimately results in significant morbidity and mortality.

Kidney involvement is a prominent feature and is the main cause of premature death in classic Fabry disease. It develops as a result of the progressive accumulation of GL-3 in the renal endothelium and other kidney cell types. Microalbuminuria, proteinuria, and isosthenuria may be apparent in adolescence and early adulthood. Progressive kidney disease is marked by the progression of proteinuria, an increase in serum creatinine levels, and the reduction of the glomerular filtration rate (GFR) during the third decade of life. Long-term hemodialysis is often required, and renal transplantation is usually successful.

Fabry-related cardiovascular disease is a key cause of premature death. Early signs of cardiac involvement include interventricular septal and left ventricular hypertrophy (LVH) associated with valvular regurgitation.

Clinical signs of congestive heart failure may accompany the progressive concentric LVH and diastolic dysfunction observed in advanced stages of the disease. Mitral valve prolapse and thickening may also be observed.

Common initial electrocardiographic abnormalities include sinus bradycardia, nonspecific ST-segment changes, T-wave inversion, and shortened PR interval.

Conduction system involvement may be observed as early as the second decade of life, and, as it progresses, the risk of lethal arrhythmias and sudden death increases.

Permanent cardiac pacing is needed in approximately 10-20% of patients.

Damage to the coronary vascular bed may lead to angina pectoris, variant angina, and myocardial infarction.

Predominant involvement of small, penetrating vessels has been reported. This involvement does not necessarily follow the typical patterns observed in atherosclerosis.

CNS involvement may be observed on brain MRI as white matter changes. This involvement may be noted as early as the second or third decade of life, typically occurring earlier in males than in females. The primary ischemic-hypoxic damage in CNS results from prothrombotic and occlusive abnormalities, in addition to large-vessel ectasias. Patients may present with transient ischemic attacks, vascular thromboses, seizures, or hemorrhagic or ischemic stroke.

Paroxysmal attacks of severe rotational vertigo occur in many patients. Although these episodes are usually brief, some prolonged severe attacks require cessation of activities for several days. Megadolichobasilar compression of the vestibulocochlear nerve has been suggested as a likely cause for these episodes.

Sensorineural hearing loss has been frequently documented in patients with Fabry disease and most likely reflects vascular pathology of the inner ear.

Peripheral neuropathy in Fabry disease predominantly involves small nerve fibers. The progressive loss of temperature and pain sensation should be assessed during the physical examination.

Lymphedema of the legs is a poorly described and a less common manifestation. Often asymmetric, the symptom may start as a transient seasonal event with a tendency to become more severe and extensive over time. This manifestation presumably reflects the progressive GL-3 deposition in the lymphatic vessels and lymph nodes, compromising the lymphatic circulation.

Obstructive and constrictive lung diseases have both been documented in a subgroup of patients, often presenting as wheezing, dyspnea, or bronchitis.

Priapism has been associated with Fabry disease.

Mild anemia is probably due to decreased RBC survival.

Poor heat and exercise tolerance is commonly observed in patients. It may start at the early stages of the disease and is reported by both males and females. This poor tolerance is typically attributed to hypohidrosis and acroparesthesias and may become more pronounced in the presence of pulmonary disease or cardiomyopathy in later stages of the disease. Patients may report lack of energy and fatigue.

Previous
Next

Atypical Fabry Disease

In atypical cases, individuals with residual enzyme activity demonstrate symptoms later in life, and the symptoms are usually limited to one or a few organs. For example, individuals with atypical cardiac variants usually do not have any signs or symptoms in childhood and present mainly with cardiac disease later in adulthood. In various surveys, approximately 3-12% of patients with unexplained LVH have been diagnosed with the cardiac variant of Fabry disease.

Clinical manifestations in female carriers vary greatly because of random X-chromosome inactivation. Although carriers commonly remain asymptomatic throughout life, many demonstrate clinical symptoms as variable and severe as those of affected males. Affected females may experience early manifestations of the disease, such as acroparesthesia and GI discomfort. Their symptoms may also be as severe and progressive as those seen in males (ie, they may develop renal failure). Females who are asymptomatic at the time of initial assessment should be closely and regularly monitored for any evidence of disease manifestation.

Previous
Next

Physical

Skin symptoms

Angiokeratoma, small punctate reddish-to-bluish angiectases, may be either flat or slightly raised and may blanch with pressure. These are commonly observed as dense clusters of lesions on the umbilicus, flanks, thighs, penis, and scrotum.

Lesions in the oral mucosa and conjunctiva are observed in some patients.

Hypohidrosis and anhidrosis may be observed.

Visual symptoms

Vision is not usually impaired.

A slit-lamp examination reveals cornea verticillata, which manifests as whirl-like white-to–golden-brown opacities that extend from the center to the periphery of the cornea. Cornea verticillata is often prominent in female carriers and may play an important role in the early recognition of Fabry disease. Therefore, in females with either a positive family history or symptoms suggestive of Fabry disease, a slit-lamp examination can be very helpful.

Other possible ocular findings include lens, retinal and conjunctival changes.

Neurological symptoms

Peripheral neuropathy, specifically loss of temperature and pain sensation, has been reported.

Hearing deficit may be observed.

Lymphedema symptoms

Asymmetric involvement of the lower extremities with pitting edema has been reported in the absence of significant renal or cardiac disease.

Other symptoms

Characteristic facial appearance, such as coarse facial features, have been described by some authors.

Previous
Next

Causes

GLA, the gene that encodes α-Gal A, has been isolated and sequenced, and more than 245 different mutations (missense, nonsense, splice, deletion, and insertion errors) have been reported. Attempts to correlate genotype with clinical presentation have been confounded by the fact that very few recurrent mutations have been reported.

The typical interfamilial variability of the disease phenotype may be due to other modifying factors, which may be genetically or environmentally derived.

A study of the p.E66Q variant of GLA suggested that this variant is not involved in the progression of chronic kidney disease (CKD) in Fabry disease. In the study, Watanabe et al determined the frequency with which the p.E66Q allele occurred in patients with CKD, including 1651 who were on chronic hemodialysis and 941 who were not on hemodialysis. They found that the frequency did not significantly differ between the dialysis and nondialysis groups. Moreover, in the nondialysis patients, no significant difference was found for the estimated GFR between those with the p.E66Q allele and those with the wild-type allele.[1]

Previous
 
 
Contributor Information and Disclosures
Author

Robert J Desnick, MD, PhD Dean for Genetics and Genomics, Professor and Chairman, Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine

Robert J Desnick, MD, PhD is a member of the following medical societies: American Society for Biochemistry and Molecular Biology, Eastern Society for Pediatric Research, American College of Medical Genetics and Genomics, American Pediatric Society, American Society for Clinical Investigation, American Society for Microbiology, American Society of Human Genetics, Central Society for Clinical and Translational Research, New York Academy of Sciences, Sigma Xi, Society for Experimental Biology and Medicine, Society for Pediatric Research

Disclosure: Received consulting fee from Amicus Therapeutics for consulting; Received consulting fee from Genzyme for consulting; Received grant/research funds from Genzyme for consulting; Received royalty from Genzyme for none; Received scientific advisory board from Genzyme for none; Received consulting fee from Synageva BioPharma for none; Received stock options from Synageva BioPharma for none; Received royalty from Shire HGT for none.

Coauthor(s)

Kenneth H Astrin, PhD Associate Professor of Human Genetics, Department of Human Genetics, Mount Sinai School of Medicine

Kenneth H Astrin, PhD is a member of the following medical societies: American Society of Human Genetics

Disclosure: Nothing to disclose.

Maryam Banikazemi, MD Assistant Professor of Clinical Pediatrics, New York Medical College

Maryam Banikazemi, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Human Genetics

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Maria Descartes, MD Professor, Department of Human Genetics and Department of Pediatrics, University of Alabama at Birmingham School of Medicine

Maria Descartes, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics, American Medical Association, American Society of Human Genetics, Society for Inherited Metabolic Disorders, International Skeletal Dysplasia Society, Southeastern Regional Genetics Group

Disclosure: Nothing to disclose.

Additional Contributors

Robert D Steiner, MD Chief Medical Officer, Acer Therapeutics; Clinical Professor, University of Wisconsin School of Medicine and Public Health

Robert D Steiner, MD is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American College of Medical Genetics and Genomics, American Society of Human Genetics, Society for Inherited Metabolic Disorders, Society for Pediatric Research, Society for the Study of Inborn Errors of Metabolism

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Acer Therapeutics; Retrophin; Raptor Pharma; Veritas Genetics; Censa Pharma<br/>Received income in an amount equal to or greater than $250 from: Acer Therapeutics; Retrophin; Raptor Pharma; Censa Pharma.

David Flannery, MD, FAAP, FACMG Vice Chair of Education, Chief, Section of Medical Genetics, Professor, Department of Pediatrics, Medical College of Georgia

David Flannery, MD, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics

Disclosure: Nothing to disclose.

References
  1. Watanabe H, Goto S, Miyashita A, et al. Role of the p.E66Q variant of GLA in the progression of chronic kidney disease. Clin Exp Nephrol. 2014 Apr 10. [Medline].

  2. [Guideline] Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006 Sep. 8(9):539-48. [Medline].

  3. [Guideline] Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003 Feb 18. 138(4):338-46. [Medline]. [Full Text].

  4. Auray-Blais C, Boutin M, Gagnon R, Dupont FO, Lavoie P, Clarke JT. Urinary globotriaosylsphingosine-related biomarkers for fabry disease targeted by metabolomics. Anal Chem. 2012 Mar 20. 84(6):2745-53. [Medline].

  5. West M, Nicholls K, Mehta A, et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol. 2009 May. 20(5):1132-9. [Medline]. [Full Text].

  6. Wilcox WR, Linthorst GE, Germain DP, Feldt-Rasmussen U, Waldek S, Richards SM, et al. Anti-a-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry Registry. Mol Genet Metab. 2012 Mar. 105(3):443-9. [Medline].

  7. Trimarchi H, Canzonieri R, Schiel A, et al. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients. J Nephrol. 2016 Feb 3. [Medline].

  8. Ashton-Prolla P, Tong B, Shabbeer J, et al. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Investig Med. 2000 Jul. 48(4):227-35. [Medline].

  9. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007 Jan 16. 146(2):77-86. [Medline]. [Full Text].

  10. Banikazemi M, Desnick RJ. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?. Nat Clin Pract Nephrol. 2006 Feb. 2(2):72-3. [Medline].

  11. Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab. 2005 Aug. 85(4):255-9. [Medline].

  12. Bennett RL, Hart KA, O'Rourke E, et al. Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J Genet Couns. 2002 Apr. 11(2):121-46. [Medline].

  13. Bishop DF, Calhoun DH, Bernstein HS, et al. Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci U S A. 1986 Jul. 83(13):4859-63. [Medline]. [Full Text].

  14. Brady RO, Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. JAMA. 2000 Dec 6. 284(21):2771-5. [Medline].

  15. Bühler FR, Thiel G, Dubach UC, Enderlin F, Gloor F, Tholen H. Kidney transplantation in Fabry's disease. Br Med J. 1973 Jul 7. 3(5870):28-9. [Medline].

  16. Chien YH, Lee NC, Chiang SC, Desnick RJ, Hwu WL. Fabry Disease: Incidence of the Common Later-Onset a -Galactosidase A IVS4+919G>A Mutation in Taiwanese Newborns -- Superiority of DNA-Based to Enzyme-Based Newborn Screening for Common Mutations. Mol Med. 2012 Mar 19. [Medline].

  17. Cho ME, Kopp JB. Fabry disease in the era of enzyme replacement therapy: a renal perspective. Pediatr Nephrol. 2004 Jun. 19(6):583-93. [Medline].

  18. Colombi A, Kostyal A, Bracher R, Gloor F, Mazzi R, Tholen H. Angiokeratoma corporis diffusum--Fabry's disease. Helv Med Acta. 1967 Dec. 34(1):67-83. [Medline].

  19. Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology. 1998 Jun. 50(6):1746-9. [Medline].

  20. Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis. 2004. 27(3):385-410. [Medline].

  21. Desnick RJ, Ioannou YA, Eng CM. a-Galactosidase A deficiency: Fabry disease. Scriver CR, Beaudet AL, Sly WS, eds. In: Metabolic and Molecular Bases of Inherited Disease. 8th ed. McGraw-Hill Professional; 2001. 3733-74.

  22. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, et al. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet. 2001 Mar. 68(3):711-22. [Medline]. [Full Text].

  23. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med. 2001 Jul 5. 345(1):9-16. [Medline].

  24. Erten Y, Ozdemir FN, Demirhan B, et al. A case of Fabry's disease with normal kidney function at 10 years after successful renal transplantation. Transplant Proc. 1998 May. 30(3):842-3. [Medline].

  25. Frustaci A, Chimenti C, Ricci R, et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med. 2001 Jul 5. 345(1):25-32. [Medline].

  26. Goldman ME, Cantor R, Schwartz MF, et al. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol. 1986 May. 7(5):1157-61. [Medline].

  27. Hilz MJ, Brys M, Marthol H. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology. 2004 Apr 13. 62(7):1066-72. [Medline].

  28. Hilz MJ, Stemper B, Kolodny EH, et al. Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain. 2000 Feb. 84(2-3):361-5. [Medline].

  29. Linthorst GE, De Rie MA, Tjiam KH. Misdiagnosis of Fabry disease: importance of biochemical confirmation of clinical or pathological suspicion. Br J Dermatol. 2004 Mar. 150(3):575-7. [Medline].

  30. Morgan SH, Rudge P, Smith SJ, et al. The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency)--investigation of symptomatic and presymptomatic patients. Q J Med. 1990 May. 75(277):491-507. [Medline].

  31. Ojo A, Meier-Kriesche HU, Friedman G, et al. Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation. 2000 Jun 15. 69(11):2337-9. [Medline].

  32. Ries M, Clarke JT, Whybra C, et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics. 2006 Sep. 118(3):924-32. [Medline].

  33. Schiffmann R. Enzyme replacement in Fabry disease: the essence is in the kidney. Ann Intern Med. 2007 Jan 16. 146(2):142-4. [Medline].

  34. Schiffmann R. Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy. Acta Neurol Belg. 2006 Jun. 106(2):61-5. [Medline].

  35. Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001 Jun 6. 285(21):2743-9. [Medline].

  36. Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A. 2000 Jan 4. 97(1):365-70. [Medline]. [Full Text].

  37. von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med. 1991 Feb 7. 324(6):395-9. [Medline].

  38. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004 Jul. 75(1):65-74. [Medline]. [Full Text].

 
Previous
Next
 
Angiokeratoma is the small punctate reddish-to-bluish angiectases on the umbilicus.
Angiokeratomas are commonly observed as dense cluster of lesions on the flank and private areas.
Corneal verticillata, commonly seen in patients with Fabry disease, detectable by slit lamp examination.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.